Company news
Neurogene Inc. news in 2021
Neurogene Inc.'s news releases, calls and decks from 2021, newest first.
Neoleukin Therapeutics Announces Preclinical Data Highlighting Activity of NL-201 in Hematologic Malignancies at 63rd American Society of Hematology Annual Meeting (ASH 2021)
December 10, 2021
Neoleukin Therapeutics Presents NL-201 Preclinical Data at Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021)
November 11, 2021
Neoleukin Therapeutics Announces Third Quarter 2021 Financial Results and Corporate Update
November 3, 2021
Neoleukin Therapeutics Announces Multiple Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021)
September 30, 2021
Neoleukin Therapeutics Announces Oral Presentation at IDWeek 2021 of Data Demonstrating that NL-CVX1, a Computationally Designed De Novo Protein, Can Block Infection by SARS-CoV-2 Viral Variants of Concern
September 28, 2021
Neoleukin Therapeutics Announces Appointment of Bill Arthur, Ph.D., as Vice President and Head of Research
September 8, 2021
Neoleukin Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
September 6, 2021
Neoleukin Therapeutics Announces Second Quarter 2021 Financial Results & Provides Corporate Update
August 4, 2021
Neoleukin Therapeutics to Participate in Canaccord Genuity 41st Annual Growth Conference
August 3, 2021
Neoleukin Therapeutics to Participate in Jefferies Virtual Healthcare Conference
May 25, 2021
Neoleukin Therapeutics Announces First Quarter 2021 Financial Results and Corporate Update
May 11, 2021
Neoleukin Therapeutics Announces Initiation of Phase 1 NL-201 Trial
May 4, 2021
Neoleukin Therapeutics to Participate in BofA Securities 2021 Healthcare Conference
May 3, 2021
Neoleukin Therapeutics Announces Appointment of Priti Patel, M.D., M.S., as Chief Medical Officer
May 2, 2021
Neoleukin Therapeutics Announces Clearance to Proceed with NL-201 Phase 1 Clinical Trial in the United States
April 25, 2021
Neoleukin Therapeutics Announces Year End 2020 Financial Results
March 24, 2021
Neoleukin Therapeutics to Host 2020 Financial Results Conference Call and Webcast on March 25, 2021
March 17, 2021
Neoleukin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference
March 1, 2021
Neoleukin Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Days
February 4, 2021
Neoleukin Therapeutics Receives Clinical Hold Letter from U.S. FDA Related to CMC Assay Development for NL-201
January 7, 2021
Neoleukin Therapeutics to Present at J.P. Morgan Healthcare Conference
January 6, 2021